ArticleHuman vaccines & immunotherapeutics2025
PV-10 enhances immune responses in hepatitis B vaccination through STING pathway.
Article in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Expression and significance of INTS10 and IRF3 in chronic hepatitis B patients.Frontiers in microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the efficacy of current hepatitis B vaccines, approximately 10% of immunocompetent individuals remain non-responsive, underscoring the urgent need for novel adjuvants to enhance vaccine-induced immunity. In this study, we investigated PV-10, a 10% Rose Bengal solution, for its potential to activate the stimulator of interferon genes (STING) pathway and enhance both innate and adaptive immune responses. Through molecular docking, we demonstrated that Rose Bengal binds to the ligand-binding domain of STING with an affinity of -7.1 kcal/mol (-7.0 to -9.0 kcal/mol for moderate binding), promoting dimer stabilization via hydrophobic and hydrogen-bonding interactions. In the human acute monocytic leukemia cell line THP-1, treatment with PV-10 induced the phosphorylation of key downstream signaling proteins, including TBK1, IRF3, and NF-κB p65, and uniquely generated a high molecular weight STING band indicative of dimer formation. Cytokine profiling revealed a time-dependent increase in pro-inflammatory cytokines and chemokines following PV-10 treatment. Furthermore, in an
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.